Abstract

Treatment planning of gastrointestinal stromal tumors (GISTs) includes distinguishing GISTs from other intra-abdominal tumors and GISTs’ molecular analysis. The aim of this study was to evaluate radiomics for distinguishing GISTs from other intra-abdominal tumors, and in GISTs, predict the c-KIT, PDGFRA, BRAF mutational status, and mitotic index (MI). Patients diagnosed at the Erasmus MC between 2004 and 2017, with GIST or non-GIST intra-abdominal tumors and a contrast-enhanced venous-phase CT, were retrospectively included. Tumors were segmented, from which 564 image features were extracted. Prediction models were constructed using a combination of machine learning approaches. The evaluation was performed in a 100 × random-split cross-validation. Model performance was compared to that of three radiologists. One hundred twenty-five GISTs and 122 non-GISTs were included. The GIST vs. non-GIST radiomics model had a mean area under the curve (AUC) of 0.77. Three radiologists had an AUC of 0.69, 0.76, and 0.84, respectively. The radiomics model had an AUC of 0.52 for c-KIT, 0.56 for c-KIT exon 11, and 0.52 for the MI. The numbers of PDGFRA, BRAF, and other c-KIT mutations were too low for analysis. Our radiomics model was able to distinguish GISTs from non-GISTs with a performance similar to three radiologists, but less observer dependent. Therefore, it may aid in the early diagnosis of GIST, facilitating rapid referral to specialized treatment centers. As the model was not able to predict any genetic or molecular features, it cannot aid in treatment planning yet.

Highlights

  • Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal tract, with an estimated incidence between 10 and 15 cases per million persons per year [1, 2]

  • The aim of this study was to evaluate whether radiomics based on Computed tomography (CT) is capable of (1) differentiating GISTs from other intra-abdominal tumors resembling GISTs prior to treatment, i.e., the differential diagnosis and (2) predicting the presence and type of mutation (BRAF, PDGFRA, and c-KIT) and the mitotic index (MI) of GISTs, i.e., the molecular analysis, called “radiogenomics”

  • Their individual predictive power was low (AUC of 0.56 for KVP, 0.60 for slice thickness), which is supported by the inter-quartile ranges being the same in GISTs and non-GISTs (KVP: (100.0, 120.0), slice thickness: (3.0, 5.0))

Read more

Summary

Introduction

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal tract, with an estimated incidence between 10 and 15 cases per million persons per year [1, 2]. The most common tumor locations are the stomach (56%) and the small intestine (32%) [2]. Differentiating GISTs from other intra-abdominal tumors (non-GISTs) is highly important for early diagnosis and treatment planning [3]. Due to the rarity of GISTs, establishing the correct diagnosis can be challenging. Computed tomography (CT) is the imaging modality of choice in GIST diagnosis [4], but assessment through an invasive tissue biopsy is generally required [5]. A non-invasive and quicker method may aid in the early assessment of GISTs, allowing rapid transfer of such patients to specialized treatment centers

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call